oseltamivir / Generic mfg. - LARVOL DELTA

A Surprising Twist in the Case of a Patient Beyond the Brink of Illness: The Rare Culprit Behind the Colitis (ATS 2025) - "He was given vancomycin, cefepime, doxycycline, and oseltamivir...The patient was treated with ganciclovir, which ultimately led to the resolution of his symptoms...In this case, the patient's multiple risk factors for ischemic colitis contributed to the condition allowing for CMV reactivation. Although rare in immunocompetent individuals, CMV colitis should be considered in cases of intractable colitis, where conventional approaches have been inconclusive."

Clinical • Cardiovascular • Cough • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Hypertension • Immunology • Infectious Disease • Influenza • Metabolic Disorders • Musculoskeletal Pain • Pain • Peptic Ulcer • Pulmonary Disease • Respiratory Diseases • Vasculitis

Role of Intravenous Immunoglobulin in Treatment of Influenza-associated Myositis: A Case Report (ATS 2025) - "A month prior, she tested positive for Influenza A at an urgent care after experiencing upper respiratory symptoms, followed by complete resolution with Oseltamivir...However, it has demonstrated a positive role in treating several forms of inflammatory myositis, with randomized controlled trials supporting its use in dermato-myositis. Our case underscores the importance of conducting further studies to determine the safety and efficacy of IVIG in debilitating viral myositis."

Case report • Clinical • CNS Disorders • Complement-mediated Rare Disorders • Dermatomyositis • Immunology • Infectious Disease • Influenza • Musculoskeletal Pain • Myositis • Otorhinolaryngology • Pain • Pulmonary Disease • Respiratory Diseases

Rapidly Fatal Hemophagocytic Lymphohistiocytosis Secondary to Influenza in a Young Adult With Sickle Cell Disease (ATS 2025) - "He received broad spectrum antibiotics with vancomycin, metronidazole, and cefepime, along with oseltamivir...Treatments for HLH include IVIG, high dose steroids, and if tolerated, rituximab or etoposide...Physicians should maintain suspicion for HLH in atypical presentation of viral infection. Further studies are needed to investigate the association of HLH and SCD."

Clinical • Cardiovascular • Genetic Disorders • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Hepatology • Immunology • Infectious Disease • Influenza • Nephrology • Pediatrics • Rare Diseases • Respiratory Diseases • Sickle Cell Disease • Ventricular Tachycardia • IL2 • IL6 • TNFA

An Unexpected Myriad of Pulmonary Complications Following Vaping and Anabolic Steroid Use (ATS 2025) - "He was treated with oseltamivir and ceftriaxone...He was treated with ampicillin-sulbactam, required chest tube placement and pressors in the setting of obstructive shock...Early transfer to ECMO-capable centers should be prioritized to enhance patient outcomes in severe cases. Monitoring patients with a history of vaping or steroid use for complications is essential, as their clinical presentations may differ from conventional cases."

Acute Respiratory Distress Syndrome • Cardiovascular • Cough • Hematological Disorders • Infectious Disease • Influenza • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Treatments Patterns in US Patients Hospitalized for Viral Lower Respiratory Tract Disease: An Analysis of Linked Electronic Health Records and Claims Data (2015-2023) (ATS 2025) - "Over half of patients (52.9%) received antivirals; remdesivir (68.6%) and oseltamivir (30.1%) were most frequently received...Immunomodulators were received by 7.5% of patients; of whom 67.6% received tocilizumab and 33.9% baricitinib... Treatment patterns with anti-infective and anti-inflammatory drugs varied over time and by viral etiology and increased with clinical severity. High use of SCSs and antibiotics across viral etiologies indicates the limited treatment options for severe viral LRTD and the need for further management options."

Clinical • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Invasive Aspergillosis (ATS 2025) - "Patient had a recent hospitalization for influenza requiring treatment with oseltamivir...She was started on broad-spectrum antibiotics and voriconazole...She was able to be extubated and was transitioned to oral posaconazole...Vaccination is hypothesized to reduce hospitalizations by preventing mucous hypersecretion associated with infection, which prevents the nidus for secondary infection. Further studies are needed to evaluate influenza vaccination's role in reducing IAPA for patients with COPD."

Cardiovascular • Chronic Obstructive Pulmonary Disease • Hematological Disorders • Human Immunodeficiency Virus • Immunology • Infectious Disease • Influenza • Neutropenia • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases

Hobby Turned Hypoxic Respiratory Failure: A Case of Mushroom Grower's Disease (ATS 2025) - "He tested positive for influenza type B. However, despite treatment with oseltamivir and inhaled bronchodilators, his symptoms persisted...Serology can be useful in identification of typical causative agents. As demonstrated in our case, history taking is crucial in diagnosis of HP, and repeated interview may be necessary in select patients, especially if the response to the treatment is inadequate,"

Clinical • Cough • Eosinophilia • Fibrosis • Immunology • Infectious Disease • Inflammation • Influenza • Pneumonia • Pulmonary Disease • Respiratory Diseases • CD4 • CD8

Rapid Respiratory Compromise Secondary to Atypical Bacterial Pneumonia Leading to Multiorgan Failure and Profound Refractory Shock (ATS 2025) - "Subsequently, patient developed profound shock and hypoxia requiring inhaled epoprostenol, paralysis, and proning...Antibiotics were deescalated to penicillin G, clindamycin, and oseltamivir with the addition of IVIG, steroids, and multiple pressors including methylene blue due to concerns for necrotizing pneumonia and toxic shock syndrome...Additionally, the significant mortality rate associated with invasive disease warrants further discussion into additional treatment modalities and early recognition of this pathogen to aid in the cessation of disease progression to multiorgan failure due to toxic shock syndrome. This case aims to highlight a case of a young individual with no comorbid conditions who rapidly progressed despite maximal therapies and focuses on the importance of early recognition in an atypical patient population."

Dermatology • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Influenza • Leukemia • Metabolic Disorders • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • Septic Shock

Explosive Pleuritis and Parapneumonic Effusion: A Group A Streptococcus-induced Pneumonia Crisis (ATS 2025) - "Case report: A 57-year-old male with a history of hypertension, gout, and asthma presented with worsening shortness of breath after been diagnosed with influenza and started on Tamiflu two days back...He was treated with ceftriaxone, azithromycin, clindamycin, steroids, and nebulization. During his hospital stay, he developed atrial fibrillation with rapid ventricular response, which was managed with Eliquis and Lopressor. A repeat chest x-ray showed bilateral ill-defined opacities, prompting escalation of antibiotics to Zosyn, while he completed a 3-day course of clindamycin...Explosive pleuritis may confer higher morbidity and mortality, thus early recognition and treatment is imperative. Thoracocentesis and pleural fluid analysis with early chest tube drainage is necessary with unresolved cases needing surgical interventions."

Asthma • Atrial Fibrillation • Cardiovascular • Gout • Heart Failure • Hypertension • Immunology • Infectious Disease • Inflammatory Arthritis • Influenza • Pneumonia • Respiratory Diseases • Rheumatology

Staphylococcus Auricularis: A Rare Case of Bacteremia in a Young Critically Ill Patient (ATS 2025) - "The patient was continued on Tamiflu and vancomycin as per infectious disease recommendations. Through this case, it is our goal to increase awareness of the potential for Staphylococcus Auricularis to cause significant disease, despite its low virulence. Thus, it is important to recognize it as a possible cause for infection in critically ill patients."

Clinical • Cough • Genetic Disorders • Infectious Disease • Influenza • Obesity • Pneumonia • Respiratory Diseases

Variability of Clinician Recommendations for Oseltamivir in Children Hospitalized With Influenza. (PubMed, Pediatrics) - "Our results demonstrate nonadherence to national recommendations and variability in oseltamivir treatment for children hospitalized with influenza, indicating uncertainty and disagreement regarding which patients benefit from antivirals. A randomized controlled trial of oseltamivir in hospitalized children is needed to help strengthen current influenza treatment recommendations and inform clinicians of treatment benefit in specific pediatric populations."

Clinical • Journal • Infectious Disease • Influenza • Pediatrics • Respiratory Diseases

Seroprevalence of anti-influenza antibodies in humans and characterization of seasonal influenza viruses isolated in Russia during the 2023-2024 flu season. (PubMed, Arch Virol) - "All of the tested isolates were susceptible to oseltamivir and zanamivir, including two A(H1N1)pdm09 strains with an NA-S247N substitution. Seroprevalence analysis showed that 60%, 54%, and 46% of the human blood samples tested were seropositive for the A(H3N2), A(H1N1)pdm09 and B/Victoria antigens from the 2022-2023 vaccine."

Journal • Infectious Disease • Influenza • Respiratory Diseases

A Review of Pediatric Influenza. (PubMed, Pediatr Ann) - "Treatment primarily involves neuraminidase inhibitors, like oseltamivir; although, therapies, such as baloxavir marboxil, are also effective. [Pediatr Ann. 2025;54(5):e174-e178.]."

Journal • Review • Gastrointestinal Disorder • Infectious Disease • Influenza • Pediatrics • Respiratory Diseases

National Respiratory Surge Forecasting With Combined Pharmacy and Public Health Data (ISPOR 2025) - "This research explored opportunities to use pharmacy and public health data to predict future surges. The datasets utilized in this study included location-specific testing results for respiratory viruses (influenza viruses and SARS-COV-2), antiviral prescription (nirmatrelvir/ritonavir for treating COVID-19 and oseltamivir for treating influenza) claims, over-the-counter (OTC) treatment sales, and SARS-COV-2 viral levels detected in nationwide wastewater monitoring data collected by CDC. Our model successfully leveraged multiple data sources in forecasting the respiratory illness trend nationally. It can proactively inform of geographic variation of impending surges for public awareness and seasonal planning."

Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Evaluating the Value of Over-the-Counter Oseltamivir for Influenza: A Cost-Utility Analysis From U.S. Payer and Societal Perspectives (ISPOR 2025) - "Reclassifying oseltamivir as an OTC medication is a cost-effective strategy from both payer and societal perspectives, supporting improved access and broader public health benefits."

HEOR • Infectious Disease • Influenza • Respiratory Diseases

A comparison of national seasonal influenza treatment guidelines across the Asia Pacific region. (PubMed, PLOS Glob Public Health) - "All guidelines recommend oseltamivir in line with WHO recommendations, although rationale and evidence reviews were often missing...The variability in recommendations and definitions highlight the need for a stronger evidence base with direct comparisons of antiviral treatment for hard and soft endpoints, and improvements in systematic guideline development. Established treatment guidelines are a key component of national influenza response strategy and in the post-covid pandemic era, renewed attention to seasonal influenza management is surely warranted."

Journal • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Repurposing Oseltamivir Against CAG Repeat Mediated Toxicity in Huntington's Disease and Spinocerebellar Ataxia Using Cellular and Drosophila Model. (PubMed, ACS Omega) - "Moreover, the identified U.S. FDA-approved drug effectively mitigated polyQ-induced toxicity in both HD cells and the Drosophila model of the disease. The results obtained from this drug repurposing approach are indicative of the neuro-shielding role of Oseltamivir in HD and several SCAs, paving the way for its translation into clinical practice to benefit patients afflicted with these devastating diseases."

Journal • Ataxia • CNS Disorders • Huntington's Disease • Movement Disorders

In Vitro and In Silico Studies on the Anti-H1N1 Activity of Bioactive Compounds from Marine-Derived Streptomyces ardesiacus. (PubMed, Mar Drugs) - "The molecular docking results demonstrated that 1-acetyl-β-carboline exhibited binding affinities comparable to Tamiflu, the positive control drug, with LibDock scores of 81.89, 77.49, and 89.21 for CDC25B, PARP1, and PTGS2, respectively, compared to Tamiflu's scores of 84.34, 86.13, and 91.29. These findings highlight the potential of the active compound 1-acetyl-β-carboline from S. ardesiacus as a novel anti-influenza agent, offering insights into their molecular mechanisms of action. The results support further in vitro and in vivo studies to validate the observed inhibitory mechanisms and therapeutic applications against H1N1 Influenza A."

Journal • Preclinical • Infectious Disease • Inflammation • Influenza • Respiratory Diseases • CDC25B • GNRP • PACERR • PARP1 • PTGS2

Unraveling Poland's unprecedented influenza surge in early 2025: increased viral severity or post-pandemic vulnerability? (PubMed, Pharmacol Rep) - "The observed surge likely reflects a post-pandemic phenomenon in a vulnerable, aging, comorbid, and largely unvaccinated population. The findings highlight the urgent need for enhanced influenza vaccination strategies in high-risk groups in Poland, as well as the importance of maintaining continuous antiviral availability throughout the epidemic season. Further research encompassing full-season comparisons and incorporating virological, immunological, and health system factors are warranted to better understand the drivers of such surges and guide future preparedness efforts."

Journal • Chronic Kidney Disease • Infectious Disease • Inflammation • Influenza • Nephrology • Pulmonary Disease • Renal Disease • Respiratory Diseases

"From GI Origin to Multisystem Metastasis: A Case of Advanced Carcinoid Syndrome" (ENDO 2025) - "Despite initial treatment with lanreotide and everolimus, adherence was poor due to fear of side effects...Management included a heparin drip for splenic infarct (later switched to Eliquis), oseltamivir for influenza, and supportive care...Treatment aims to cure localized disease or palliate symptoms in advanced cases, with early palliative care integration essential for improving quality of life.*. .*"

Clinical • Metastases • Carcinoid Syndrome • Cardiovascular • Chronic Kidney Disease • Colorectal Cancer • Diabetes • Diabetic Nephropathy • Endocrine Cancer • Fibrosis • Gallbladder Cancer • Gastrointestinal Disorder • Hepatocellular Cancer • Hepatology • Hypotension • Immunology • Infectious Disease • Influenza • Lung Cancer • Metabolic Disorders • Neuroendocrine Tumor • Oncology • Ophthalmology • Palliative care • Peritoneal Cancer • Pulmonary Arterial Hypertension • Pulmonary Disease • Renal Disease • Respiratory Diseases • Septic Shock • Solid Tumor • Type 2 Diabetes Mellitus • SSTR

Improving Antiviral Use in Children Hospitalized with Influenza (PAS 2025) - "Outcome measure was the percentage of encounters with at least one dose of a hospital formulary antiviral (oseltamivir or peramivir) administered. Baseline consisted of 143 encounters with antiviral treatment administered in 74.8% of encounters. There has not been a shift in the center line in the outcome measure, though 7 of last 8 points are above centerline (Figure 2). Special cause variation (SCV) was seen in our process measure with a shift in the center line from 4.9 hours to 2.4 hours following educational interventions (Figure 3)."

Clinical • Infectious Disease • Influenza • Pediatrics • Respiratory Diseases

Clinician preferences for oseltamivir treatment of children with influenza in the outpatient setting (PAS 2025) - "Of 1124 eligible participants, 425 (37.8%) completed surveys. Wave analysis demonstrated no association between survey response time and likelihood to recommend oseltamivir. Participants were somewhat or extremely likely to recommend oseltamivir in 36.2% of cases, however there was variability by specialty from 29.6% to 48.6% (p < 0.001), and study site from 28.6% to 50.7% (p < 0.001)."

Clinical • Infectious Disease • Influenza • Pediatrics • Respiratory Diseases

Anitvirals for Children Hospitalized with Influenza: Oseltamivir (guidelines) Make(s) Me Nauseous (Dove) (PAS 2025) - No abstract available

Clinical • Infectious Disease • Influenza • Respiratory Diseases

Variability of provider preferences for oseltamivir use in children hospitalized with influenza (PAS 2025) - No abstract available

Clinical • Infectious Disease • Influenza • Respiratory Diseases

How to manage antivirals in critically ill patients with Influenza? (PubMed, Clin Microbiol Infect) - "Neuraminidase inhibitors constitute the vast majority of antivirals currently prescribed for influenza. The most commonly prescribed NAI to date is oseltamivir. While its efficacy in non-severe cases of influenza is well established, the evidence for its efficacy in critically ill patients is based on less robust studies, as no randomised controlled trials have been conducted in this population. Limited data on oseltamivir pharmacokinetics is available in critically ill patients. The selection of A(H1N1)pdm09 resistant variants to oseltamivir is particularly problematic in critically-ill patients hospitalised in intensive care units. Data on other antivirals, including NAIs (i.e., zanamivir, peramivir and laninamivir) or baloxavir marboxil in critically ill patients are scarce. Further research is needed to develop new drugs and assess their efficacy in critically ill patients and to better assess the effect of oseltamivir in this population."

Journal • Review • Critical care • Infectious Disease • Influenza • Respiratory Diseases